Royalty Report: Drugs, Disease, Pharmaceuticals – Collection: 341530

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 16

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 16

Primary Industries

  • Drugs
  • Disease
  • Pharmaceuticals
  • Gastrointestinal
  • Therapeutic
  • Pain
  • Ulcer
  • Autoimmune
  • Bacterial Infection

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 341530

License Grant
Under the terms of the new arrangement, Belgium Licensee will assume all development, manufacturing, commercialization and certain other rights for filgotinib in Europe.
License Property
Filgotinib preferential JAK1 inhibitor with a potential best-in-class product profile (Jyseleca). Janus kinases (JAK) are critical components of signaling mechanisms utilized by a number of cytokines and growth factors, including those that are elevated in RA. Filgotinib is a preferential JAK1 inhibitor. Jyseleca® is the brand name for filgotinib
Field of Use
Field of Use is for the treatment of IBD (Inflammatory Bowel Disease), CD (Crohns Disease), UC (Ulcerative Colitis) and potentially other inflammatory diseases such as RA (Rheumatiod arthritus).

Inflammatory Bowel Disease (IBD) This is a general term for an autoimmune disease affecting the bowel, including CD and UC. CD affects the small and large intestine, while UC affects the large intestine. Both diseases involve inflammation of the intestinal wall, leading to pain, bleeding, and ultimately, in some cases, surgical removal of part of the bowel.

Crohn’s disease (CD) An IBD involving inflammation of the small and large intestines, leading to pain, bleeding, and ultimately in some cases surgical removal of parts of the bowel.

Ulcerative colitis (UC) An IBD causing chronic inflammation of the lining of the colon and rectum (unlike CD with inflammation throughout the gastrointestinal tract).

Rheumatoid arthritis (RA) A chronic, systemic inflammatory disease that causes joint inflammation, and usually leads to cartilage destruction, bone erosion and disability.

Inflammatory diseases is a large, unrelated group of disorders associated with abnormalities in inflammation.

IPSCIO Record ID: 7344

License Grant
The Licensee entered into an exclusive License Agreement (with a right to subLicense) with the Licensor, a nonprofit medical research facility, for the rights to novel modulators of sphingosine phosphate receptors, including modulators to the S1P1R.
License Property
The technology Licensed covers RPC1063.

RMS  RPC1063 is a novel, oral, once daily, selective and potent S1P1R modulator. RMS is a chronic autoimmune disorder of the central nervous system (CNS), characterized by recurrent acute exacerbations (relapses) of neurological dysfunction followed by variable degrees of recovery with clinical stability between relapses (remission).

RPC1063 for the treatment of UC IBD is comprised of two chronic, autoimmune, GI inflammatory disorders UC and Crohn's Disease (CD). UC is a GI inflammatory disorder involving ulcers in the colon and is characterized by a chronic course of remissions and exacerbations. Patients suffer from a multitude of GI symptoms, including diarrhea, rectal bleeding and abdominal pain.

Field of Use
RPC1063, is being developed as an oral therapy for the treatment of Relapsing Multiple Sclerosis (RMS) and Inflammatory Bowel Disease (IBD).

IPSCIO Record ID: 263902

License Grant
The Licensor of Germany grants, in respect of the Licensor Patents, the Licensor IP and the Licensor Product Data the sole and exclusive royalty bearing right and license to use the same and to develop, use and Exploit the Product throughout the Territory and a non-exclusive right and license to manufacture and have manufactured the Product in any part of the world for Exploitation in the Territory only.
License Property
The licensed property is a pellet formulation of mesalamine.  

The name of the product is Salofalk® 500 mg, Granu-Stix®.   Salofalk Granu-Stix delivers the therapeutically active antiinflammatory agent mesalamine (5-aminosalicylic acid or 5-ASA) to the distal ileum and colon by means of dual-release granules.

The patents include Pellet formulation for the treatment of the intestinal tract,  and, Pellet-type formulation intended for treating the intestinal tract.

Field of Use
The field of use is for the treatment of acute episodes and the maintenance of remission of ulcerative colitis.
Ulcerative colitis (UC) is a disease that affects your large intestine, or colon. It causes irritation and swelling called inflammation. … UC is a type of inflammatory bowel disease, but it's different from other diseases with similar symptoms, like Crohn's disease or irritable bowel syndrome.

IPSCIO Record ID: 281500

License Grant
Under the Filgotinib Amendment Agreement, the Company has greater involvement in filgotinib’s global strategy, and will participate more broadly in the commercialization of the product in Europe, providing the opportunity to build a commercial presence on an accelerated timeline. The Company and Irish Licensee will co-commercialize filgotinib in France, Germany, Italy, Spain and the United Kingdom and retain the 50/50 profit share in these countries that was part of the original filgotinib license agreement dated 16 December 2015, and under the Filgotinib Amendment Agreement, the Company will have an expanded commercial role. The Company retains exclusive rights in Belgium, the Netherlands and Luxembourg, where the 50/50 profit share also applies.
License Property
Filgotinib is a Janus kinase inhibitor with selectivity for subtype JAK1 of this enzyme. It is considered a promising agent as it inhibits JAK1 selectively.  It shows long-term efficacy in the treatment of various inflammatory diseases.

Licensor discovers and develops small molecule medicines with novel modes of action, three of which show promising patient results and are currently in late-stage development in multiple diseases.

Field of Use
Filgotinib is a drug for the treatment of rheumatoid arthritis and Crohns disease.

IPSCIO Record ID: 372413

License Grant
The Licensor Parties grant an exclusive, world-wide license to make, have made, use, lease, import, offer for sale and sell Licensed Products and to use the method under Patent Rights and Technical information, to the extent not prohibited by other patents, in the Field of Use.
License Property
The Licensor Parties are the owners of the Method Patent and a pending patent entitled Treatment of Inflammatory and Ulcerative Diseases of the Bowel with Opioid Antagonists and one Licensor is the owner/Sponsor of IBD FDA IND#, FDA orphan drug designation x-2969 and a pending patent for Treatment of Inflammatory and Ulcerative Diseases of the Bowel with Opioid Antagonists.
Field of Use
The term Field of Use means development, production, use, and storage of Licensed Products, alone or in combination with other treatments, for the prevention and/or treatment of Crohn's disease and other inflammatory and ulcerative diseases of the bowel.
Crohn's disease is a type of inflammatory bowel disease (IBD) that may affect any segment of the gastrointestinal tract from the mouth to the anus

IPSCIO Record ID: 372409

License Grant
The German Licensor hereby grants to the Company an exclusive license in the Field to practice under the Patent Rights and to utilize the Know-how in the Territory, and (a) to make, have made, use, have used, lease, import, offer to sell, sell and/or have sold the Licensed Products and to practice and have practiced the Licensed Processes, to the full end of the term for which the Patent Rights are granted, unless sooner terminated as hereinafter provided and (b) to sublicense to third parties.
License Property
UIRF is, therefore, owner by assignment from Joel Weinstock and David Elliott of their entire right, title and interest in United States Patent 6,764,838 and United States Patent Application Numbers 09/362,598; 10/715,659; 10/779,249; Canada Patent Application Number 2,315,790; Japanese Patent Application Number 2000-526233; Australia Patent Number 740776, all titled “Use of Parasitic Biological Agents for Prevention and Control of Autoimmune Diseases”.

The following comprise PATENT RIGHTS
United States Patent Number 6,764,838
United States Patent Application Numbers 09/362,598; 10/715,659; 10/779,249

Field of Use
“Field” shall mean the prevention, treatment, cure or diagnosis of human diseases, with the exception of gastroenterology (e.g., inflammatory bowel disease) and hepatology in Europe.

These patents claim methods of producing a pharmaceutical preparation comprising an helminthic parasite preparation, pharmaceutical compositions suitable for oral administration comprising an isolated and purified T.suis helminthic parasite preparation, and methods of treating inflammatory bowel disease, including Crohn’s and UC, in an individual by the administration of a T. suis helminthic parasite preparation, respectively.

CNDO-201 is a biologic product candidate comprising TSO for the treatment of autoimmune diseases. We initially plan to investigate TSO for the treatment of Crohn’s, UC and MS.

The use of helminths in the treatment of autoimmune disease is based on the belief that the immune systems of populations living in the relatively sterile environments found in developed countries with little or no exposure to parasites may develop in abnormal ways. This “hygiene hypothesis” is based on epidemiologic findings of an inverse relationship between automimmune diseases and helminthic colonization. The incidence of IBD is highest in the developed world and in temperate climates, with positive correlations noted among persons of higher socioeconomic status and high levels of domestic hygiene experienced in childhood. Conversely, the incidence of IBD is rare in less developed countries and in persons with blue-collar jobs involving exposure to dirt and physical exercise.

In contrast to the epidemiologic findings of IBD, the prevalence of helminths is highest in warm climates and in populations characterized by crowding, poor sanitation, and impure food supply. Furthermore, the incidence of IBD has increased over the past several decades, while the prevalence of helminths in the United States and Europe has steadily declined during the same time period. These findings have led to the idea that eliminating intestinal helminths in the industrialized world has eliminated a natural T regulatory cell mechanism that prevents excessive T-cell activation such as occurs in IBD as well as in other immune-mediated diseases such as MS, asthma and allergies.

The immunologic basis for helminth therapy for IBD is derived from experimental animal and human data demonstrating that these organisms alter immune responses beyond those directed against the worms. In animal models, helminths blunt Th1 responses and promote Th2 responses associated with increased production of IL-4 and IL-3. Helminthic colonization in humans can result in diminished Th1 immune responses to challenges with unrelated antigens, as well as increased production of immunomodulatory molecules such as IL-10, transforming growth factor (TGF)-ß, and regulatory T-cells. Thus, genetically susceptible persons who are never exposed to helminths may lack a strong Th2 immune response and develop a poorly regulated and destructive intestinal Th1 response, leading to chronic colitis or ileitis.

IPSCIO Record ID: 210693

License Grant
The Licensor granted the Licensee an exclusive worldwide license to develop, manufacture and commercialize PTG-200 and other IL-23R compounds covered by our patent rights that meet certain requirements for all indications of inflammatory bowel disease,IBD, including CD – Crohns disease and UC – ulcerative colitis.
License Property
The Licensor is a biopharmaceutical company with a proprietary technology platform utilized to discover and develop oral targeted therapy-based peptide drugs including PTG-200 for treatments including the treatment of CD and UC.
Field of Use
The Licensee entered the collaboration agreement for the development, manufacture and commercialization of PTG-200 worldwide.

IPSCIO Record ID: 256198

License Grant
For the Licensor Pre-Clinical Know-How License and Patent Rights License, and, Data Delivery,  The German Licensor grants an exclusive right and license, including the right to grant sublicenses, under the Licensor Pre-Clinical Know-How and Patent Rights to
–   Develop, use, Commercialize, sell, offer for sale and import Product in the Licensee Territory, and,
–   subject, as between Licensee and the Third Party, to the terms of the Third Party/Licensee Agreements, have Product made by Third Party, make and have made Product.

For the Cross-Licenses, Pre-Clinical Data and Clinical Data Sharing, Licensor grants
–   an exclusive right and license, including the right to grant sublicenses, to and under Pre-Clinical Data and Clinical Data that is or becomes during the term of this Agreement owned or Controlled by Licensor to develop, use, import, sell, offer for sale, and Commercialize Product in the Field in the Licensee Territory, and subject, as between Licensee and the Third Party, to the terms of the Third Party/Licensee Agreements, have Product made by the Third Party, make and have made Product; and
–   consents to Licensees right of reference and use of such Pre-Clinical Data and Clinical Data in connection with Regulatory Filings in the Licensee Territory.

License Property
The Product shall mean any pharmaceutical or medicinal product containing Trichuris suis ova (TSO) as the active ingredient, incorporated into any formulation or delivery system, intended for use in the prevention, treatment or cure of any human disease or condition.

Trichuris suis ova shall mean the ova or eggs of the Trichuris suis worm.

The U.S. Patent Application Nos. 12/594,074 and 12/993,517 are related to the Product.

Field of Use
The Field of use shall mean the prevention, treatment or cure of Crohns disease and/or ulcerative colitis.

Crohn's disease is an inflammatory bowel disease (IBD). It causes inflammation of your digestive tract, which can lead to abdominal pain, severe diarrhea, fatigue, weight loss and malnutrition.
Ulcerative colitis is a chronic disease of the large intestine, also known as the colon, in which the lining of the colon becomes inflamed and develops tiny open sores, or ulcers, that produce pus and mucous.

IPSCIO Record ID: 264191

License Grant
The Company executed a license agreement with the University for a worldwide, exclusive license to manufacture, market, sell and sublicense Extracellular Matrix Hydrogel.
License Property
ExtraCellular Matrix Hydrogel (“ECMH”), targets the treatment of multiple gastrointestinal diseases, including Ulcerative Colitis, Crohn’s Disease, and Rectal Mucositis.
Field of Use
This agreement pertains to the drug industry with a field of use limited to human and animal colonic and small intestine therapeutic indications.

ExtraCellular Matrix Hydrogel (ECMH), is a first-in-class, non-pharmacologic, non-surgical treatment option for patients suffering from Ulcerative Colitis.
Ulcerative colitis (UC) is a long-term condition that results in inflammation and ulcers of the colon and rectum. The primary symptoms of active disease are abdominal pain and diarrhea mixed with blood. Weight loss, fever, and anemia may also occur.

IPSCIO Record ID: 28777

License Grant
The Canadian Licensor grant to the Canadian Licensee any right in or transfer title to the Project Technology, Intellectual Property, or in any applicable technology incorporated in Special-Purpose Equipment, including the assignment, sale, licence and lease to any person from a program of the Canadian government.
License Property
Products' means the ALX 0600 compound as well as formulations thereof, a peptide analog of human glucagon-like peptide-2[GLP-2] for the treatment of various intestinal disorders for the treatment of any disease and other applications, approved by any regulatory authorities, worldwide.
Field of Use
Licensee are independently developing ALX-0600 for the treatment of short bowel syndrome and Crohn’s Disease. ALX-0600 is an analog of glucagon-like peptide 2, a naturally occurring hormone that regulates proliferation of the cells lining the small intestine. Animal studies indicate that ALX-0600 stimulates the repair and regeneration of cells lining the small intestine, expanding the surface area for absorption of nutrients. In animal studies, ALX-0600 induced an approximately 50 percent increase in the weight of the small intestine within 10 days of administration. Further, these studies suggest the growth-promoting properties of ALX-0600 appear to be highly tissue-specific, predominantly affecting the small intestine, and thereby potentially reducing the risk of adverse side effects.

ALX-0600 may also be useful in treating other gastrointestinal conditions characterized by malabsorption, altered absorptive capacity and inflammation or deterioration of the intestinal wall. Examples of these conditions include inflammatory bowel disease, like Crohn’s Disease, and intestinal mucositis in cancer patients.

IPSCIO Record ID: 289928

License Grant
The Company entered a joint venture with Chinese Licensor to further develop and commercialize ONS-3010 with Licensor in the agreed countries.
License Property
The Phase I ONS-3010 trial demonstrated pharmacokinetic (PK) bioequivalence on the primary and secondary endpoints for the biosimilar candidate and the US and EU originator product (Humira).

ONS-3010 is a subcutaneous injectable mAb that binds to tumor necrosis factor alpha, or TNFa. TNFa belongs to a family of pro-inflammatory cytokines, or soluble protein mediators, that are key initiators of immune-mediated inflammation in many different diseases, such as rheumatoid arthritis, psoriatic arthritis, psoriasis, ankylosing spondylitis, Crohn’s disease and ulcerative colitis. Several biologic agents, including Humira, have been developed to inhibit the inflammatory activity of TNFs in the context of these diseases and are collectively referred to as the anti-TNF class of therapeutics.

Humira, the reference product for ONS-3010, is a subcutaneous injectable mAb that binds to tumor necrosis factor alpha, or TNFa. TNFa belongs to a family of pro-inflammatory cytokines, or soluble protein mediators, that are key initiators of immune-mediated inflammation in many different diseases, such as rheumatoid arthritis, psoriatic arthritis, psoriasis, ankylosing spondylitis, Crohn’s disease and ulcerative colitis. Several biologic agents, including Humira, have been developed to inhibit the inflammatory activity of TNFs in the context of these diseases and are collectively referred to as the anti-TNF class of therapeutics.

Field of Use
Humira is used to treat many inflammatory conditions in adults, such as ulcerative colitis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, and a skin condition called hidradenitis suppurativa.

IPSCIO Record ID: 359530

License Grant
Licensee acquires IMU-838 and IMU-935 from German Licensor.
License Property
IMU-838, targets DHODH, a key enzyme in the intracellular metabolism of immune cells in the body. The IMU-838 program is focused on the development of oral formulations of small molecule inhibitors of the enzyme dihydroorotate dehydrogenase (“DHODH”).

IMU-935, is a highly potent and selective inverse agonist of a transcription factor called ROR?t with additional activity on DHODH. IMU-935 program is focused on an inverse agonist of ROR?t, an immune cell-specific isoform of retinoic acid receptor-related orphan nuclear receptor gamma (“ROR?”).

Field of Use
Field of use is for selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, including relapsing-remitting multiple sclerosis (“RRMS”), ulcerative colitis (“UC”), Crohn’s disease (“CD”) and psoriasis.

IPSCIO Record ID: 233469

License Grant
The Licensor of England grants to Licensee of Bermuda the exclusive right and license under the Patent Rights, the Technical Information and Manufacturing Technology to develop, have developed, make, have made, use, sell and have sold Products within the Territory. Notwithstanding the foregoing, Licensor may authorize a Specific Third Party, its Affiliates and successors to manufacture Balsalazide within the Territory solely for sale and use outside the Territory.
License Property
The patents and technology are related to Balsalazide, or to prodrugs, analogs or isomers thereof or improvements of any of the foregoing, obtained in any country within the Territory.

Balsalazide means 5-[4(2-Carboxyethelcarbamoyl)-phenylazo] – salicylic acid disodium salt dihydrate.

Products means products incorporating Balsalazide, whether or not such products are covered by the Patent Rights, or any other material whose manufacture, use or sale by an unlicensed third party would constitute an infringement of any Valid Claim included within the Patent Rights.

Field of Use
The product is used for gastrointestinal disease.

First marketed product, Colazal, was the first new molecular entity approved in 10 years by the FDA for the treatment of mildly to moderately active ulcerative colitis and the first new oral therapy approved by the FDA for this indication in seven years.  Ulcerative colitis is a chronic form of inflammatory bowel disease characterized by inflammation of the lining of the colon. Symptoms of active ulcerative colitis include rectal bleeding, abdominal pain, increased stool frequency, loss of appetite, fever and weight loss.

IPSCIO Record ID: 239024

License Grant
The Licensor of Spain grants to an exclusive, even as to Licensor, license under the Patent Assets and the Licensor Know-How, including the right to grant sublicenses, to develop, make, have made, use, import, offer for sale, promote, market, commercialize, distribute and sell Product in the Territory, and insofar as necessary for the purposes of exercising such rights, to develop, make, have made, use, import, offer for sale, commercialize, distribute and sell Compound.
License Property
The compound is UR-12746 Sodium Salt, meaning UR-12746 (including UR-12715) and UR-12746(S), and any derivative, homolog or analog of any of the foregoing or any isomer, salt, hydrate, solvate, amide, ester, metabolite, or prodrug of any of the foregoing, and any pharmaceutical composition containing any of the foregoing in any pharmaceutically acceptable form.

Licensor possesses significant expertise in the field of antiinflammatory therapeutics, and dersalazine represents the culmination of years of internal research.

Dersalazine is a new chemical entity that combines a well-known anti-inflammatory agent, 5-ASA, with a novel potent agent that acts as a PAF antagonist and an inhibitor of key interleukin cytokines to achieve a synergistic therapeutic effect when compared to the activities of each component separately. Chemical cleavage of dersalazine by colonic bacteria releases the two active compounds for the topical treatment of inflammation in the colon. The 5-ASA molecule contained in dersalazine has known antioxidant properties which may ameliorate the deleterious inflammatory effects ascribed to the overproduction of free radicals.

Field of Use
Dersalazine is a compound in early clinical development to treat Inflammatory Bowel Disease (IBD), which includes ulcerative colitis and Crohn's disease.

IPSCIO Record ID: 29002

License Grant
The collaboration agreement for the provision of Inflammatory Bowel Disease patient samples and IBD clinical  data.

IPSCIO Record ID: 266736

License Grant
Licensor, a non-profit hospital, grants to Licensee to the extent of the Licensed Territory an exclusive license under the patent rights to make, have made, use, sell and have sold, and import licensed products in the Licensed Field, with the right to sub license.

Licensor grants to the extent of the Licensed Territory a nonexclusive license to use the Licensed Technology as necessary to exploit all rights granted with respect to the patent rights in the Licensed Field, with the right to sublicense.

License Property
Licensor owns US Patent application for Methods of Treating Irritable Bowel Syndrome and Other Disorders Caused by Small Intestinal Bacterial Overgrowth, and, US Patent entitled Methods of Diagnosing or Treating Irritable Bowel Syndrome and Other Disorders Caused by Small Intestinal Bacterial Overgrowth.

Rifaximin means rifaximin, any pharmaceutical equivalents, salts and derivatives thereof.

Field of Use
Rifaximin is an antibiotic used to treat traveler's diarrhea, irritable bowel syndrome, and hepatic encephalopathy.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.